Stoke Therapeutics, Inc. STOK Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Viridian Therapeutics, Inc.VRDN

——

Tango TherapeuticsTNGX

——

Septerna, Inc.SEPN

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: Stoke Therapeutics, Inc. (STOK) reported proceeds from issuance of common stock relating to employee stock plans of $465K in Q1 2026.
How has Stoke Therapeutics, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Stoke Therapeutics, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 25.7% year-over-year, from $370K to $465K.